Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Predictmedix ( (TSE:PMED) ).
QScreen AI Inc. has completed its corporate rebranding and name change from Predictmedix AI, with its shares now expected to trade under the new symbol QAI on the Canadian Securities Exchange while leaving its share capital, operations, management and strategic direction unchanged, and requiring no action from existing shareholders. The new identity reflects the company’s evolution from a narrow health screening focus to a broader screening, inference and decision-intelligence platform that integrates quantum-inspired and advanced computational techniques with classical machine learning, aimed at enhancing signal detection, performance in data-heavy, time-sensitive environments and scalability across enterprise and government deployments as it moves to commercialize quantum-enhanced AI screening technologies and onboard strategic talent to support global growth.
The most recent analyst rating on (TSE:PMED) stock is a Hold with a C$0.06 price target. To see the full list of analyst forecasts on Predictmedix stock, see the TSE:PMED Stock Forecast page.
Spark’s Take on TSE:PMED Stock
According to Spark, TipRanks’ AI Analyst, TSE:PMED is a Neutral.
The score is held down primarily by very weak financial performance (minimal revenue, persistent losses, negative free cash flow, and negative equity). Technicals are mixed but not strongly bearish, and recent corporate announcements/financings are supportive; however, valuation is constrained by ongoing losses and the lack of a dividend yield.
To see Spark’s full report on TSE:PMED stock, click here.
More about Predictmedix
QScreen AI Inc., formerly Predictmedix AI, is an emerging provider of rapid health screening and remote patient care solutions, focused on healthcare, safety and related high-value markets. Its Smarthealth AI stations use proprietary artificial intelligence and multispectral imaging to analyze physiological data and predict a range of health issues, including vital signs, impairment, fatigue and mental health conditions, while its remote patient care platform offers AI-powered tools to support clinicians and improve patient outcomes globally.
YTD Price Performance: -21.43%
Average Trading Volume: 225,529
Technical Sentiment Signal: Buy
Current Market Cap: C$11.37M
For detailed information about PMED stock, go to TipRanks’ Stock Analysis page.